Leerink Partners Increases Vir Biotechnology (NASDAQ:VIR) Price Target to $20.00
Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price objective raised by Leerink Partners from $18.00 to $20.00 in ...
Vir Biotechnology Receives Buy Rating: Promising TCE Programs and Strategic Focus Boost Growth Outlook
Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) on January 13 and set a price target ...
Strategic Acquisition of Life Molecular Imaging Boosts Lantheus’ Position in Alzheimer’s Radiodiagnostic Market
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Stay Ahead of the ...
MobiDB20h
Medical biotechnologies
A course delivered entirely in English, with an international approach, teaching the methods and instruments of biotechnology for the prevention, diagnosis and therapy of human diseases. You will deal ...
What's on Netflix17h
Netflix News
Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...
cryptonews8h
Latest Crypto News
Sygnum Crypto Bank Raises $58M, Achieves Unicorn Status with $1B Valuation ...